VS-7375 for Colorectal Cancer

(TARGET-D 203 Trial)

This trial tests a new treatment, VS-7375, for individuals with metastatic colorectal cancer that has a specific KRAS G12D mutation. Researchers aim to determine if VS-7375 is safe and effective alone or when combined with other drugs like cetuximab or panitumumab, and in some cases, a chemotherapy regimen called mFOLFOX. Ideal candidates for this trial have already received standard chemotherapy for their metastatic colorectal cancer and have experienced disease progression. As a Phase 2 trial, this research focuses on assessing the treatment's effectiveness in an initial, smaller group, offering participants a chance to contribute to significant advancements in cancer treatment.

The trial requires stopping certain medications before starting. You must stop taking strong CYP3A4 inhibitors/inducers or sensitive substrates within 14 days, and PPIs or H2 blockers within 5 days before the first treatment dose.

Research has shown that VS-7375 was generally well-tolerated in earlier studies. At doses of 400 mg and 600 mg per day, no serious side effects prevented dose escalation, indicating patients could handle these amounts without major issues.

Further findings reveal that VS-7375 remains safe even at higher doses, such as 600 mg and 900 mg daily. Most side effects were mild and manageable, suggesting the treatment is quite safe for patients with conditions similar to those in the current trial.

Researchers are excited about VS-7375 for colorectal cancer because it offers a fresh approach compared to standard treatments like chemotherapy and targeted therapies such as cetuximab and bevacizumab. VS-7375 is unique as it targets specific pathways involved in cancer cell growth, potentially offering a more precise attack on tumors with fewer side effects. In the trial, VS-7375 is being tested alone and in combination with other treatments like cetuximab and mFOLFOX, which may enhance its effectiveness. This innovative strategy could lead to more personalized and effective treatment options for patients with colorectal cancer.

Research has shown that the drug VS-7375 yields promising results for patients with KRAS G12D-mutated tumors. In an earlier study, four out of five patients experienced tumor shrinkage after using VS-7375, suggesting the drug can help reduce tumor size. Another study with lung cancer patients who had the same mutation found that 68.8% responded well to the treatment, indicating a positive reaction in most cases. In this trial, participants will receive VS-7375 either as monotherapy or in combination with other treatments. These findings suggest that VS-7375 could effectively treat cancers with the KRAS G12D mutation, including colorectal cancer.¹²⁴⁶⁷